It facilitates the binding of the PP1 catalytic subunit to glycogen granules, aiding in the process of glycogen metabolism.[22, 25, 28]PPP1R3B, a key regulator of glycogen metabolism, is a critical metabolic regulatory site intricately linked to the risk of developing ASCVD.[27, 29, 30] In glycogen metabolism, PPP1R3B influences glycogen synthesis by modulating the dephosphorylation of glycogen synthase and glycogen phosphatase via PP1.[25] Dephosphorylation activates glycogen synthase, increasing glycogen synthesis, but inactivates glycogen phosphatase, decreasing glycogen breakdown.[22]. The gene discussed is EPM2A; the disease is atherosclerosis.